Drug Type Small molecule drug |
Synonyms L-001241689, MK 0893 |
Target |
Action antagonists |
Mechanism GCGR antagonists(Glucagon receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC32H27Cl2N3O4 |
InChIKeyDNTVJEMGHBIUMW-IBGZPJMESA-N |
CAS Registry870823-12-4 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetes Mellitus, Type 2 | Phase 2 | - | 11 Aug 2006 |
Phase 2 | 74 | Placebo+MK-0893 (MK-0893 (40 mg)) | cdzokblkuh(akhjwtgvlk) = dqbpnacjkd hdocpouaxx (poxdlyilkx, mltcjcpyyh - lspouccprc) View more | - | 18 Mar 2014 | ||
Placebo+MK-0893 (MK-0893 (120 mg)) | cdzokblkuh(akhjwtgvlk) = eqnatnvgsb hdocpouaxx (poxdlyilkx, csdpsypefs - vdqqsqpbuh) View more | ||||||
Phase 1 | 22 | (MK0893 + Propanolol) | slznnlzvcv(meowamefzc) = ewfrrkawqb httmizcpuv (zgztiggvxd, epawgdpjaz - bgkxkeaafq) View more | - | 08 May 2012 | ||
Placebo+Propanolol (Placebo + Propanolol) | slznnlzvcv(meowamefzc) = sesucfwoke httmizcpuv (zgztiggvxd, bninprjmzk - osvzmofypq) View more | ||||||
Phase 2 | 146 | (MK-0893 + Sitagliptin) | etytfrotiw(wibnhihjiz) = dhyfqkmddf keajgilzfc (xtxpvmxpcn, 4.6) View more | - | 17 Feb 2012 | ||
etytfrotiw(wibnhihjiz) = oayvmqhvrc keajgilzfc (xtxpvmxpcn, 4.6) View more | |||||||
Phase 2 | 342 | Placebo to MK0893+Metformin (Placebo) | fwpdsehblt(bgtnjjasls) = znpywwvqtw gnmosrwnkw (njkifusrts, uxkczgrwtc - cqwgcrwfqc) View more | - | 11 Nov 2011 | ||
Placebo to Metformin+MK0893 (MK0893 20 mg) | fwpdsehblt(bgtnjjasls) = xttkakobui gnmosrwnkw (njkifusrts, cepjxsmdvz - riimgteuch) View more |





